Comparative Pharmacology
Head-to-head clinical analysis: JANUMET versus METFORMIN HYDROCHLORIDE AND SITAGLIPTIN PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JANUMET versus METFORMIN HYDROCHLORIDE AND SITAGLIPTIN PHOSPHATE.
JANUMET vs METFORMIN HYDROCHLORIDE AND SITAGLIPTIN PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Janumet is a combination of sitagliptin, a DPP-4 inhibitor, and metformin, a biguanide. Sitagliptin increases incretin levels (GLP-1, GIP), enhancing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Metformin: Activates AMP-activated protein kinase (AMPK), reducing hepatic glucose production, decreasing intestinal glucose absorption, and improving insulin sensitivity. Sitagliptin: Inhibits dipeptidyl peptidase-4 (DPP-4), increasing incretin levels (GLP-1, GIP), enhancing glucose-dependent insulin secretion and suppressing glucagon release.
Initial dose: 50 mg sitagliptin/500 mg metformin hydrochloride twice daily orally with meals. Dose may be increased up to 50 mg sitagliptin/1000 mg metformin twice daily based on glycemic response and tolerability.
Oral, 50 mg sitagliptin/500 mg metformin twice daily with meals. Maximum: 100 mg sitagliptin/2000 mg metformin per day in divided doses.
None Documented
None Documented
Sitagliptin: 12.4 hours (terminal). Clinical context: supports once-daily dosing, but half-life increases in renal impairment. Metformin: 6.2 hours (terminal). Shorter half-life requires multiple daily dosing; prolonged in renal impairment.
Metformin terminal half-life ~6.2 hours (prolonged in renal impairment; clinical context: dosing adjustment required if eGFR <45 mL/min). Sitagliptin terminal half-life ~12.4 hours (extended in renal impairment; dose adjustment for CrCl <50 mL/min).
Sitagliptin: 87% renal (unchanged), 13% fecal (metabolites). Metformin: 90-100% renal (unchanged), <5% fecal.
Metformin is excreted unchanged in urine (90% renal tubular secretion) and feces (10%). Sitagliptin is excreted primarily unchanged in urine (87% renal, 13% fecal via biliary).
Category C
Category A/B
DPP-4 Inhibitor/Biguanide Combination
DPP-4 Inhibitor